title: An in vitro comparison of the effects of voluven (6% hydroxyethyl starch 130/0.4) and hespan (6% hydroxyethyl starch 670/0.75) on measures of blood coagulation in canine blood.
abstract: OBJECTIVE
  To assess primary and secondary hemostasis following in vitro dilution of canine whole blood (WB) with hydroxyethyl starch (HES) 130/0.4 and HES 670/0.75.
  
  
  METHODS
  In vitro experimental study.
  
  
  METHODS
  Private practice, teaching hospital.
  
  
  METHODS
  Twenty-five healthy dogs.
  
  
  METHODS
  Each dog underwent venipuncture and 18 mL of venous blood was sampled once.
  
  
  RESULTS
  Collected blood was separated in 4 aliquots. Aliquot A served as baseline sample. The remaining tubes of WB were diluted with 0.9% saline, HES 670/0.75 and HES 130/0.4 at a ratio of 1:5.5. Dilutional effects were evaluated using prothrombin time (PT), activated partial thromboplastin time (aPTT), packed cell volume (PCV), thromboelastography (TEG), and platelet closure time (Ct), which was measured using a platelet function analyzer (PFA). Clot strength (ie, G value) was calculated from measured TEG values. Significant increases in PT (P < 0.05) and aPTT (P < 0.05) were documented following WB dilution with saline. Dilution of WB with HES 670/0.75 and HES 130/0.4 resulted in significant hypocoagulable changes in K, MA and G (P < 0.05) compared to baseline and saline. When comparing saline to HES 670/0.75, both R and K values were significantly increased (P < 0.05). K value was significantly increased (P < 0.05) when comparing baseline to HES 130/0.4 and HES 670/0.75. Ct (P < 0.05) was significantly prolonged after WB dilution with HES solutions but not after saline.
  
  
  CONCLUSIONS
  Dilution of WB with HES 670/0.75 and HES 130/0.4 resulted in changes in primary and secondary hemostasis. Although there were small differences between saline and HES 670/0.75, no differences between HES solutions were evident in this small study. This may suggest there would be minimal increases in bleeding risk when either solution is administered to dogs at low doses. Clinical relevance of our findings requires further investigation.
authors.affiliation: Department of Emergency and Critical Care, The Animal Medical Center, New York, NY, 10065.
authors.forename: Michelle
authors.initials: M
authors.lastname: Griego-Valles
authors.affiliation: Department of Emergency and Critical Care, The Animal Medical Center, New York, NY, 10065.
authors.forename: Yekaterina
authors.initials: Y
authors.lastname: Buriko
authors.affiliation: Department of Emergency and Critical Care, The Animal Medical Center, New York, NY, 10065.
authors.forename: Jennifer E
authors.initials: JE
authors.lastname: Prittie
authors.affiliation: Department of Emergency and Critical Care, The Animal Medical Center, New York, NY, 10065.
authors.forename: Philip R
authors.initials: PR
authors.lastname: Fox
mesh_terms: D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests / Q000662:veterinary; D004285:Dogs; D005260:Female; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D013916:Thrombelastography / Q000662:veterinary
chemical_list: C485123:HES 130-0.4; D006895:Hydroxyethyl Starch Derivatives
keywords: TEG; coagulopathy; dogs; hemostasis; synthetic colloids